Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10224	Companies
210793	Keywords
140753	Articles
111678	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 08/01/2025 at 13:00, 8 months 14 days ago

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Moderna reports Q2 revenue of $0.1B, net loss of $(0.8)B, updates 2025 revenue to $1.5-$2.2B due to shipment timing, improves operating expenses by $400M, reiterates $6B year-end cash balance. FDA approvals for flu vaccine

Revenue Moderna Q2 2025 FDA Approvals
BRIEF

published on 08/01/2025 at 12:05, 8 months 14 days ago

UK Court Confirms Validity of Moderna's EP'949 Patent

Patent MRNA Technology Moderna Pfizer/BioNTech UK Court
PRESS RELEASE

published on 08/01/2025 at 12:00, 8 months 14 days ago

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Moderna's EP'949 patent validity upheld by UK Court of Appeal in Pfizer/BioNTech case. Recent legal developments in Europe further strengthen Moderna's intellectual property portfolio

MRNA Technology Moderna Pfizer/BioNTech EP'949 Patent UK Court Of Appeal
BRIEF

published on 07/30/2025 at 22:10, 8 months 16 days ago

Moderna Gains European Approval for New COVID-19 Vaccine

COVID-19 Vaccine European Commission Moderna SARS-CoV-2 SPIKEVAX®
PRESS RELEASE

published on 07/30/2025 at 22:05, 8 months 16 days ago

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna receives marketing authorization from the European Commission for updated COVID-19 vaccine Spikevax® targeting SARS-CoV-2 variant LP.8.1

COVID-19 Vaccine European Commission Moderna Spikevax LP.8.1
BRIEF

published on 07/28/2025 at 13:05, 8 months 18 days ago

Moderna to Present mRNA Therapeutics Data at ESMO Congress 2025

MRNA Therapeutics Moderna Melanoma Bladder Cancer ESMO Congress 2025
PRESS RELEASE

published on 07/28/2025 at 13:00, 8 months 18 days ago

Moderna Announces Data to be Presented at ESMO Congress 2025
Moderna to present abstracts on investigational mRNA therapeutics at 2025 ESMO Congress. Mini oral presentation on mRNA-4359 and two poster presentations on intismeran autogene

Cancer Therapy MRNA Therapeutics Moderna ESMO Congress T-cell Immune Responses
BRIEF

published on 07/25/2025 at 14:50, 8 months 21 days ago

EMA Recommends Moderna's Updated COVID-19 Vaccine for EU Authorization

COVID-19 Vaccine European Commission Moderna EMA Approval SARS-CoV-2 LP.8.1
PRESS RELEASE

published on 07/25/2025 at 14:45, 8 months 21 days ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine targeting variant LP.8.1 receives positive CHMP opinion for EU marketing authorization. European Commission to decide for 2025-2026 season

COVID-19 Vaccine European Commission Moderna CHMP LP.8.1
BRIEF

published on 06/30/2025 at 13:05, 9 months 15 days ago

Moderna Reports Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna Influenza Vaccine Phase 3 Results RVE MRNA-1010

Accesswire

Published on 04/16/2026 at 01:50, 1 hour 29 minutes ago

Challenger DFS Pit Optimisation Drilling Complete
Published on 04/15/2026 at 23:00, 4 hours 19 minutes ago

EV Nickel Intersects 1.20% Nickel Over 9.80 Metres at Langmuir South
Published on 04/15/2026 at 22:30, 4 hours 49 minutes ago

Avant Brands Announces its Annual General and Special Meeting
Published on 04/15/2026 at 22:15, 5 hours 4 minutes ago

APPULSE CORPORATION (Listed on the TSX Venture Exchange - Symbol 'APL') - Reporting Results for the 2025 Fiscal Year and Adoption of Semi-annual Reporting
Published on 04/15/2026 at 22:00, 5 hours 19 minutes ago

NioCorp to Participate in Maxim Group's "Mining the Industrial Supply Chain" Conference on Apr. 21

View all ACCESSWIRE

EQS Group

Published on 04/15/2026 at 22:50, 4 hours 29 minutes ago

AIXTRON SE successfully placed EUR 450 million convertible bonds
Published on 04/15/2026 at 22:47, 4 hours 31 minutes ago

EQS-Adhoc: AIXTRON SE successfully placed EUR 450 million convertible bonds
Published on 04/15/2026 at 22:35, 4 hours 44 minutes ago

Gerresheimer: Broad Support from Creditors / Creditors agree to extend the due date / Sales process for Centor Inc. launched as planned
Published on 04/15/2026 at 22:23, 4 hours 55 minutes ago

EQS-Adhoc: Gerresheimer AG: Creditors agree to extend the due date for submitting the audited 2025 annual and consolidated financial statements
Published on 04/15/2026 at 21:05, 6 hours 14 minutes ago

EQS-Adhoc: Advanced Blockchain AG: Change in the Management Board

Les Echos

Published on 04/15/2026 at 20:12, 7 hours 7 minutes ago

Covivio - Q1 2026 activity : Strategic progress driving growth
Published on 04/15/2026 at 18:43, 8 hours 35 minutes ago

SFPI GROUP: publication des résultats 2025
Published on 04/15/2026 at 17:45, 9 hours 34 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2026
Published on 04/15/2026 at 07:30, 19 hours 49 minutes ago

Covivio Hotels - Revenues at end-March 2026 : +1.4% Revenue growth year-on-year
Published on 04/15/2026 at 07:30, 19 hours 49 minutes ago

Covivio is accelerating its expansion in the hotel sector with the acquisition of four hotels in Milan for €217 million

View all LES ECHOS COMFI WIRE